{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T12:50:28Z","timestamp":1774356628887,"version":"3.50.1"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metastatic pancreatic ductal adenocarcinoma (mPDAC) is one of the most aggressive malignancies with a very poor prognosis. Currently, there is no standardized therapeutic approach for third-line systemic treatment. The aim of this retrospective\/prospective study was to evaluate survival outcomes in patients treated in the third-line setting and to analyze the impact of nutritional and inflammatory biomarkers on overall survival (OS) and progression-free survival (PFS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The analysis retrospectively and prospectively included 95 patients with mPDAC treated with third-line systemic therapy. Data were collected from the Slovak Pancreas Registry. Data were collected from 13 hospitals. Baseline chemotherapy regimens, ECOG, nutritional, and inflammatory parameters were recorded and used to calculate prognostic scores (PNI, CRP, NLR, SII, SIRI, GPS). Their association with OS and PFS was analyzed using the log-rank test and Kaplan-Meier survival analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The most frequently used regimen was FOLFOX\/CAPOX (56 patients), followed by nanoliposomal irinotecan (nal-IRI, 24 patients) and capecitabine (11 patients). The median OS was 5.55 months and the median PFS was 3.29 months. A PNI &amp;gt; 40.5 was significantly associated with longer OS (6.34 vs. 3.32 months,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.001) and PFS (3.71 vs. 2.76 months,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.009). Lower GPS scores were significantly associated with improved OS (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.006) and PFS (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.027). Other inflammatory markers (NLR, SIRI, SII, CRP) did not show a statistically significant impact on OS or PFS.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Third-line systemic therapy may offer clinical benefit in selected mPDAC patients, particularly in those with favorable nutritional-inflammatory profiles. The Prognostic Nutritional Index (PNI) and Glasgow Prognostic Score (GPS) appear to be potentially useful tools for identifying candidates suitable for further systemic treatment. However, further prospective studies are needed to confirm these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1713376","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T11:52:48Z","timestamp":1774353168000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Survival outcomes and prognostic value of nutritional and inflammatory markers in third-line treatment of metastatic pancreatic cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"J\u00falia","family":"Vidulin","sequence":"first","affiliation":[{"name":"Department of Oncology, Faculty Hospital","place":["Tren\u010d\u00edn, Slovakia"]},{"name":"1st Department of Oncology, Faculty of Medicine, Comenius University in Bratislava and St. Elisabeth Cancer Institute","place":["Bratislava, Slovakia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dalibor","family":"Ondru\u0161","sequence":"additional","affiliation":[{"name":"1st Department of Oncology, Faculty of Medicine, Comenius University in Bratislava and St. Elisabeth Cancer Institute","place":["Bratislava, Slovakia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u015atefan","family":"P\u00f6r\u0161\u00f6k","sequence":"additional","affiliation":[{"name":"2nd Department of Oncology, Faculty of Medicine, Comenius University in Bratislava and National Cancer Institute","place":["Bratislava, Slovakia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melinda","family":"Kr\u00e1\u010dal\u00edkov\u00e1","sequence":"additional","affiliation":[{"name":"2nd Department of Oncology, Faculty of Medicine, Comenius University in Bratislava and National Cancer Institute","place":["Bratislava, Slovakia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanda","family":"U\u0161\u00e1kov\u00e1","sequence":"additional","affiliation":[{"name":"1st Department of Oncology, Faculty of Medicine, Comenius University in Bratislava and St. Elisabeth Cancer Institute","place":["Bratislava, Slovakia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristi\u00e1n","family":"\u0160ut\u00e1k","sequence":"additional","affiliation":[{"name":"Department of Oncology, Faculty Hospital","place":["Trnava, Slovakia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michaela","family":"Mi\u0161kovi\u010dov\u00e1","sequence":"additional","affiliation":[{"name":"Department of Oncology, Faculty Hospital","place":["Nitra, Slovakia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00edna","family":"Kizekov\u00e1","sequence":"additional","affiliation":[{"name":"Department of Oncology, F. D. Roosevelt University Hospital","place":["Bansk\u00e1 Bystrica, Slovakia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maro\u0161","family":"Fremal","sequence":"additional","affiliation":[{"name":"Department of Oncology, Merciful Brothers Hospital","place":["Bratislava, Slovakia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jana","family":"Pis\u00e1kov\u00e1","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy and Oncology, Faculty of Medicine, PJ Safarik University and Eastern Slovakia Institute of Oncology","place":["Ko\u0161ice, Slovakia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Kecsk\u00e9s","sequence":"additional","affiliation":[{"name":"Oncology Centre, University Hospital","place":["Martin, Slovakia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaroslava","family":"Le\u0161kov\u00e1","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty Hospital","place":["Pre\u0161ov, Slovakia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Branislav","family":"Bystrick\u00fd","sequence":"additional","affiliation":[{"name":"Department of Oncology, Faculty Hospital","place":["Tren\u010d\u00edn, Slovakia"]},{"name":"Faculty of Healthcare, Alexander Dub\u010dek University of Tren\u010d\u00edn","place":["Tren\u010d\u00edn, Slovakia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.08.009","article-title":"Pancreatic cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up\u2020","volume":"34","author":"Conroy","year":"2023","journal-title":"Ann Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1251258","article-title":"Third-line treatment options in metastatic pancreatic cancer patients: A real-world study","volume":"13","author":"Lu","year":"2023","journal-title":"Front Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.pan.2025.01.012","article-title":"The efficacy and safety profile of third-line treatment in patients with metastatic pancreatic adenocarcinoma","volume":"25","author":"Lan","year":"2025","journal-title":"Pancreatology"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v17.i2.100167","article-title":"Identification of patients with advanced pancreatic cancer who might benefit from third-line chemotherapy","volume":"17","author":"Kim","year":"2025","journal-title":"World J Gastrointest Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz422.058","article-title":"The emerging role of third-line gemcitabine plus nab-paclitaxel in advanced pancreatic adenocarcinoma","volume":"30","author":"Dean","year":"2019","journal-title":"Ann Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.113950","article-title":"A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for \u22653rd-line treatment of patients with advanced pancreatic adenocarcinoma","volume":"201","author":"Enzler","year":"2024","journal-title":"Eur J Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf125","article-title":"Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cancer: A cohort-based study","volume":"30","author":"Evrard","year":"2025","journal-title":"Oncologist"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(194811)1:4%3C634::aid-cncr2820010410%3E3.0.co;2-l","article-title":"The Use of the Nitrogen Mustards in the Palliative Treatment of Carcinoma.With Particular Reference to Bronchogenic Carcinoma","volume":"1","author":"Karnofsky","year":"1948","journal-title":"Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1159\/000503095","article-title":"Performance status assessment by using ECOG (Eastern Cooperative Oncology Group) score for cancer patients by oncology healthcare professionals","volume":"12","author":"Azam","year":"2019","journal-title":"Case Rep Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.26717\/bjstr.2021.34.005524","article-title":"The usefulness of prognostic nutritional index in predicting infection in patients with newly diagnosed pancreatic cancer","volume":"34","author":"Manojlovic","year":"2021","journal-title":"Biomed J Sci Tech Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-014-1714-3","article-title":"The prognostic significance of the prognostic nutritional index in cancer: A systematic review and meta-analysis","volume":"140","author":"Sun","year":"2014","journal-title":"J Cancer Res Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"28","DOI":"10.12998\/wjcc.v7.i1.28","article-title":"Correlation of serum albumin and prognostic nutritional index with outcomes following pancreaticoduodenectomy","volume":"7","author":"Rungsakulkij","year":"2019","journal-title":"World J Clin Cases"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fsurg.2022.992641","article-title":"Prognostic role of the prognostic nutritional index in patients with pancreatic cancer who underwent curative resection without preoperative neoadjuvant treatment: A systematic review and meta-analysis","volume":"9","author":"Zhao","year":"2022","journal-title":"Front Surg"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-012-2348-9","article-title":"The Glasgow prognostic score as a predictor of survival in patients with potentially resectable pancreatic adenocarcinoma","volume":"19","author":"La Torre","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19950415)75:8%3C2077::aid-cncr2820750808%3E3.0.co;2-9","article-title":"Acute-phase protein response and survival duration of patients with pancreatic cancer","volume":"75","author":"Falconer","year":"1995","journal-title":"Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602305","article-title":"Systemic\u00a0inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma head of pancreas","volume":"92","author":"Jamieson","year":"2004","journal-title":"Br J Cancer"},{"key":"B17","article-title":"Prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: A retrospective analysis","volume":"28","author":"Papadoniou","year":"2008","journal-title":"Anticancer Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/jso.20329","article-title":"Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer","volume":"91","author":"Walsh","year":"2005","journal-title":"J Surg Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i9.2807","article-title":"Prognostic significance of neutrophil to lymphocyte ratio in pancreatic cancer: A meta-analysis","volume":"21","author":"Yang","year":"2015","journal-title":"World J Gastroenterol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/2373868","article-title":"Neutrophil to lymphocyte ratio as a predictor of poor prognosis in metastatic pancreatic cancer patients treated with nab-paclitaxel plus gemcitabine: A propensity score analysis","volume":"2018","author":"Ventriglia","year":"2018","journal-title":"Gastroenterol Res Pract"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.pan.2019.12.010","article-title":"A systemic inflammation response index (SIRI) correlates with survival and predicts oncological outcome for mFOLFIRINOX therapy in metastatic pancreatic cancer","volume":"20","author":"Pacheco-Barcia","year":"2020","journal-title":"Pancreatology"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v16.i2.386","article-title":"Systemic inflammation response index and weight loss as prognostic factors in metastatic pancreatic cancer: A concept study from the PANTHEIA-SEOM trial","volume":"16","author":"Pacheco-Barcia","year":"2024","journal-title":"World J Gastrointest Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1042\/bsr20204401","article-title":"Prognostic significance of the systemic immune-inflammation index in pancreatic carcinoma patients: A meta-analysis","volume":"41","author":"Li","year":"2021","journal-title":"Biosci Rep"},{"key":"B24","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1245\/s10434-019-08094-0","article-title":"Prognostic value of the systemic immune-inflammation index (SII) after neoadjuvant therapy for patients with resected pancreatic cancer","volume":"27","author":"Murthy","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12016-z","article-title":"Pancreatic adenocarcinoma third line systemic treatments: A retrospective cohort study","volume":"24","author":"Gueiderikh","year":"2024","journal-title":"BMC Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1713376\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T11:52:50Z","timestamp":1774353170000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1713376\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":25,"alternative-id":["10.3389\/fonc.2026.1713376"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1713376","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"article-number":"1713376"}}